Acute Myeloid Leukemia Cell Therapy Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs and Forecast, 2031
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Acute Myeloid Leukemia Market Report Overview
The AML market value for the 15 markets (15M) was $3.1 billion in 2021. Moreover, the high transplant relapse rate and steady increase in incidence provide a steady flow of cell therapy-eligible patients and will drive market growth during the forecast period.
Buy Full Report to Know More About the Acute Myeloid Leukemia Market Forecast
The acute myeloid leukemia market research report offers a comprehensive insight into the market through 2032. The report provides an overview of the disease including epidemiology, symptoms, diagnosis, disease management, countries where the disease is prevalent, and leading players associated with the market.
Market Size (2021) | $3.1 Billion |
Key Regions | · North America
· APAC · Europe · The Middle East |
Leading Players | · Bellicum Pharmaceuticals
· Orca Biosystems · Glycostem Therapeutics · Gamida Cell · ExCellThera |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
AML Market Dynamics
Cell therapies will struggle to compete with oral and biomarker-driven agents for defined populations such as FLT3 and IDH1/2. However, the high transplant relapse rate and steady increase in incidence provide a steady flow of cell therapy-eligible patients, which will thereby fuel the AML market growth in the coming years.
Acute Myeloid Leukemia Market Analysis by Treatment
- A subset of AML patients develops the disease following treatment with chemotherapy for other cancers or following the onset of chronic myeloproliferative disorders, like polycythemia vera, essential thrombocytopenia, idiopathic myelofibrosis, or chronic myeloid leukemia (CML).
- AML presents a few unmet needs that can be well addressed by cell therapies and the most important of these are improved outcomes after transplant and treatments in the second line and beyond.
Buy the Full Report to Know More About the Acute Myeloid Leukemia Market Treatment
AML Market Segmentation by Regions
North America had the highest share in 2021.
The key regions in the AML market are North America, APAC, Europe, and the Middle East.
AML Market Analysis by Regions, 2021
Buy Full Report to Know More Regional Insights on the AML Market
AML Market - Competitive Landscape
A few of the leading players in the AML market are
- Bellicum Pharmaceuticals
- Orca Biosystems
- Glycostem Therapeutics
- Gamida Cell
- ExCellThera
Bellicum Pharmaceuticals is the leading sponsor of cell therapy trials in AML, followed by Orca Bio.
AML Market Analysis by Companies
Buy Full Report to Get More Insights on Companies in the AML Market
Acute Myeloid Leukemia Market Region Outlook (Value, $ Billion, 2021-2032)
- North America
- APAC
- Europe
- The Middle East
Scope
- This report includes disease epidemiology, a 10-year patient-based forecast for marketed and pipeline therapies with established mechanisms of action, and cell & gene therapies by class, including early- to late clinical-stage pipeline products with launch date assessment by the 8MM market.
- The forecast includes 8 countries for the period of 2021-2031
- Seven markets are extrapolated, obtaining a 15-market value for all AML therapeutics
Reasons to Buy
- What is the target patient pool for cell & gene therapies in each cancer indication?
- Which patient groups are more likely to receive these therapies?
- What does the cell & gene therapy clinical-stage pipeline look like in each cancer indication?
- What is the anticipated breakdown between autologous and allogeneic cell therapies?
- When will cell & gene therapies launch in each market?
- What is the total market value projected for the forecast end, in 2031?
Gamida Cell
Marker Therapeutics
Table of Contents
Frequently asked questions
-
What was the acute myeloid leukemia market size in the 15M in 2021?
The acute myeloid leukemia market value for the 15 markets (15M) was $3.1 billion in 2021.
-
What are the key regions in the AML market?
The key regions in the AML market are North America, APAC, Europe, and the Middle East.
-
Which region has the highest share in the acute myeloid leukemia market?
North America has the highest share in the acute myeloid leukemia market.
-
Who are the leading players in the AML market?
A few of the leading players in the AML market are Bellicum Pharmaceuticals, Orca Biosystems, Glycostem Therapeutics, Gamida Cell, ExCellThera, Orca Biosystems, Fate Therapeutics, and Marker Therapeutics.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.